Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
4.310
+0.120 (2.86%)
At close: Jun 4, 2026, 4:00 PM EDT
4.610
+0.300 (6.96%)
After-hours: Jun 4, 2026, 7:57 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,377,704
Market Cap
13.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| BioLineRx | 24 |
| Jasper Therapeutics | 22 |
| Moleculin Biotech | 17 |
| CalciMedica | 16 |
| Theriva Biologics | 16 |
| BioVie | 13 |
| MetaVia | 8 |
CVKD News
- 1 day ago - Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event - GlobeNewsWire
- 7 days ago - Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference - Transcripts
- 16 days ago - Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Cadrenal Therapeutics Earnings release: Q1 2026 - Filings
- 4 weeks ago - Cadrenal Therapeutics Slides: Investor presentation - Filings
- 5 weeks ago - Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA - TheFly